CRISPR Therapeutics AG Advances While Market Declines Some Information for Investors
| CRSP Stock | USD 40.02 1.05 2.56% |
Slightly above 62% of Crispr Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Crispr Therapeutics AG suggests that many traders are alarmed. Crispr Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Crispr Therapeutics AG. Many technical investors use Crispr Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Crispr |
The latest trading day saw CRISPR Therapeutics AG settling at 41.07, representing a 0.32 percent change from its previous close.
Read at zacks.com
 |
Crispr Therapeutics Fundamental Analysis
We analyze Crispr Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crispr Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crispr Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Crispr Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Crispr Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Crispr Therapeutics stock to make a market-neutral strategy. Peer analysis of Crispr Therapeutics could also be used in its relative valuation, which is a method of valuing Crispr Therapeutics by comparing valuation metrics with similar companies.
Peers
Crispr Therapeutics Related Equities
| HEPA | Hepion Pharmaceuticals | 2.04 | ||||
| NVO | Novo Nordisk | 0.32 | ||||
| REGN | Regeneron Pharmaceuticals | 0.60 | ||||
| FATE | Fate Therapeutics | 0.62 | ||||
| KRYS | Krystal Biotech | 0.75 | ||||
| NTLA | Intellia Therapeutics | 1.24 | ||||
| SRPT | Sarepta Therapeutics | 1.52 | ||||
| EDIT | Editas Medicine | 1.63 | ||||
| CRBU | Caribou Biosciences | 1.76 | ||||
| VERV | Verve Therapeutics | 4.44 | ||||
| BEAM | Beam Therapeutics | 7.35 |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.